Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.
John C. Byrd
Research Funding - Pharmacyclics
Jennifer R. Brown
Consultant or Advisory Role - GlaxoSmithKline; Pharmacyclics
Honoraria - Janssen
Susan Mary O'Brien
Research Funding - Pharmacyclics
Jacqueline Claudia Barrientos
Consultant or Advisory Role - Pharmacyclics
Honoraria - Janssen
Research Funding - Pharmacyclics
Neil E. Kay
Research Funding - Pharmacyclics
Nishitha M. Reddy
Consultant or Advisory Role - Pharmacyclics
Honoraria - Janssen
Research Funding - Pharmacyclics
Steven E. Coutre
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Constantine Tam
Consultant or Advisory Role - Pharmacyclics (U)
Expert Testimony - Pharmacyclics (U)
Stephen P. Mulligan
Consultant or Advisory Role - Janssen; Pharmacyclics
Honoraria - Janssen Australia
Ulrich Jäger
Honoraria - Janssen-Cilag
Steve Devereux
Consultant or Advisory Role - Pharmacyclics
Honoraria - Pharmacyclics
Paul M. Barr
Research Funding - Pharmacyclics
Richard R. Furman
Consultant or Advisory Role - Janssen; Pharmacyclics
Honoraria - Janssen
Thomas J. Kipps
Consultant or Advisory Role - AbbVie; Celgene; Genentech; Pharmacyclics
Florence Cymbalista
Honoraria - Janssen; Pharmacyclics
Maria Fardis
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Jesse S. McGreivy
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Fong Clow
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Peter Hillmen
Consultant or Advisory Role - Pharmacyclics (U)
Honoraria - Pharmacyclics